COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease

Journal of Neural Transmission

Volumn 109, Issue 1, 2002, Pages 69-75

  Oechsner, M ^a   Buhmann, C ^b   Strauss, J ^b   Stuerenburg, H J ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

COMT inhibition; Dihydroxyphenylacetic acid; Free radicals; Levodopa; Oxidative stress; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOL METHYLTRANSFERASE INHIBITOR; DIHYDROXYPHENYLACETIC ACID; HOMOVANILLIC ACID; HYDROXYL RADICAL; LEVODOPA; TOLCAPONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG OXIDATION; DYSKINESIA; ENZYME INHIBITION; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

3,4-DIHYDROXYPHENYLACETIC ACID; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; DIHYDROXYPHENYLALANINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOMOVANILLIC ACID; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE;

EID: 0036172181     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s702-002-8237-z     Document Type: Article

References (26)

1. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
2. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa
3. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects
4. New insights into the cause of Parkinson's disease
5. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation
6. The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers
7. Tolcapone and neurotoxicity in Parkinson's disease
8. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease
9. Oxidative damage caused by free radicals produced during catecholamine autoxidation: Protective effects of O-methylation and melatonin
10. Modification of central acting dopaminergic mechanisms by continous levodopa therapy for advanced Parkinson's disease
11. Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: Is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?
12. Tolcapone increases maximum concentration of levodopa
13. Effect of entacapone, a COMT inihibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease
14. Pharmacokinetics of levodopa
15. Intravenous lisuride corrects motor oscillations in Parkinson's disease
16. Catechol-O-methyltransferase reduced levodopa toxicity in PC12 cells: Implications for treatment of Parkinson's disease
17. Oxidation reactions in Parkinson's disease
18. Selegiline: Current perspectives on issues related to neuroprotection and mortality
19. Attempts to obtain neuroprotection in Parkinson's disease
20. Role of iron and oxidant stress in the normal and parkinsonian brain
21. Control of on/off phenomenon by continous intavenous infusion of levodopa
22. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial
23. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa relatedfluctuations
24. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects
25. Acute overdosage and intoxication with carbidopa/levodopa can be detected in the subacute stage by measurement of 3-orthomethyldopa
26. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier